Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

Continue Reading

First-of-its-kind CAR T clinical trial enrolls HER2+ breast cancer patients with brain metastases

October 30, 2018 | City of Hope

City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.

Parker Institute for Cancer Immunotherapy Welcomes Stephen J. Forman, M.D.

September 27, 2018 | Letisia Marquez

City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.

City of Hope's Stephen J. Forman Joins Parker Institute for Cancer Immunotherapy

July 16, 2018 | Letisia Marquez

City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.

Inside the Lab: Preventing breast cancer from invading the brain

July 24, 2017 | Denise Heady

A study led by City of Hope neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., offers novel insights on how cancer cells in HER2-positive breast cancer develop the ability to break through the blood-brain barrier and, ultimately, how they can be stopped.

Wolf in sheep's clothing: breast cancer cloaks itself in brain proteins to invade the brain

March 14, 2017 | Denise Heady

More women than ever are surviving breast cancer only to die of secondary brain tumors years after they’ve been declared cancer-free. This is particularly true for patients with the breast cancer subtype HER2-positive. Now City of Hope researchers have discovered how this happens.